Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Sep 20;8(9):e75283.
doi: 10.1371/journal.pone.0075283. eCollection 2013.

Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis

Jincheng Pan  1 , Junxing Chen, Bo Zhang, Xu Chen, Bin Huang, Jintao Zhuang, Chengqiang Mo, Shaopeng Qiu
Affiliations
Meta-Analysis

Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis

Jincheng Pan et al. PLoS One. .

Abstract

Prostate cancer (PCa) remains as one of the most common cause of cancer related death among men in the US. The widely used prostate specific antigen (PSA) screening is limited by low specificity. The diagnostic value of other biomarkers such as RAS association domain family protein 1 A (RASSF1A) promoter methylation in prostate cancer and the relationship between RASSF1A methylation and pathological features or tumor stage remains to be established. Therefore, a meta-analysis of published studies was performed to understand the association between RASSF1A methylation and prostate cancer. In total, 16 studies involving 1431 cases and 565 controls were pooled with a random effect model in this investigation. The odds ratio (OR) of RASSF1A methylation in PCa case, compared to controls, was 14.73 with 95% CI = 7.58-28.61. Stratified analyses consistently showed a similar risk across different sample types and, methylation detection methods. In addition, RASSF1A methylation was associated with high Gleason score OR=2.35, 95% CI: 1.56-3.53. Furthermore, the pooled specificity for all included studies was 0.87 (95% CI: 0.72-0.94), and the pooled sensitivity was 0.76 (95% CI: 0.55-0.89). The specificity in each subgroup stratified by sample type remained above 0.84 and the sensitivity also remained above 0.60. These results suggested that RASSF1A promoter methylation would be a potential biomarker in PCa diagnosis and therapy.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Forest plot showing the association between RASSF1A methylation and prostate cancer.
(A) Forest plot of 16 studies showed that RASSF1A methylation was associated with PCa risk as stratified analysis by methods. (B) Forest plot after sensitivity analysis removing 6 studies showed the same risk without heterogeneity (p= 0.089). The diamond symbol represents the overall estimate from the meta-analysis and its CI (confidence interval), while its center is positioned on the value for the overall effect estimate. Diamond’s width depicts the width of the overall CI.
Figure 2
Figure 2. Meta-analysis with the S-ROC curve.
SENS: Sensitivity, SPEC: Specificity, AUC: Area under the curve.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781. - DOI - PubMed
    1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087. - DOI - PubMed
    1. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF et al. (2001) Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol 158: 399-406. doi:10.1016/S0002-9440(10)63983-1. PubMed: 11159178. - DOI - PMC - PubMed
    1. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A et al. (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46: 377-383. doi:10.1016/j.ejca.2009.09.008. PubMed: 19804966. - DOI - PubMed
    1. Barbieri CE, Demichelis F, Rubin MA (2012) Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60: 187-198. doi:10.1111/j.1365-2559.2011.04041.x. PubMed: 22212086. - DOI - PubMed

Publication types

Substances